| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S00262-004-0517-9 |
| P698 | PubMed publication ID | 15069585 |
| P50 | author | Teresa Cabrera | Q57108310 |
| Angel Garcia-Lora | Q73294001 | ||
| Federico Garrido | Q104975217 | ||
| P2093 | author name string | Ignacio Algarra | |
| Francisco Ruiz-Cabello | |||
| P433 | issue | 10 | |
| P921 | main subject | evasion of host immune response | Q1660157 |
| P304 | page(s) | 904-910 | |
| P577 | publication date | 2004-04-07 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape | |
| P478 | volume | 53 |
| Q49377125 | A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells |
| Q35626593 | A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines |
| Q35968482 | A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy |
| Q28289791 | A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis |
| Q39764766 | Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer |
| Q90189164 | Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade |
| Q58851281 | Absence of the HLA-G*0105N allele in Amerindian populations from the Brazilian Amazon Region: a possible role of natural selection |
| Q40099670 | Administration of the cytotoxic complex Tag7-Hsp70 to mice with transplanted tumors inhibits tumor growth |
| Q43460400 | Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. |
| Q81436256 | Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy |
| Q36546883 | Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions |
| Q92481897 | CAR-armed cell therapy for gliomas |
| Q33939552 | CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis |
| Q30235014 | Cancer immunotherapy: how low-level ionizing radiation can play a key role |
| Q35843507 | Challenges and future perspectives of T cell immunotherapy in cancer |
| Q43851750 | Characterisation of non-classical MHC class I genes in the Tasmanian devil (Sarcophilus harrisii). |
| Q53705286 | Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. |
| Q37414728 | Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases |
| Q36083431 | Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions |
| Q38270003 | Clinical and immunological significance of HLA-E in stem cell transplantation and cancer |
| Q42286093 | Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma |
| Q50249146 | Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region. |
| Q37989886 | Contagious cancer: lessons from the devil and the dog. |
| Q26771337 | Cord Blood as a Source of Natural Killer Cells |
| Q42144694 | Cytomegalovirus and tumors: two players for one goal-immune escape |
| Q39665364 | Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human |
| Q51826916 | Does the devil facial tumour produce immunosuppressive cytokines as an immune evasion strategy? |
| Q58143382 | Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells |
| Q38148588 | Epigenetics of melanoma: implications for immune-based therapies. |
| Q54613468 | Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. |
| Q37281015 | Expression of cancer-associated molecules in malignant mesothelioma |
| Q37394717 | Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer |
| Q36912224 | Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications |
| Q39084368 | Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer |
| Q37511055 | HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women |
| Q39800387 | HLA-G alleles and HLA-G 14 bp polymorphisms in a Brazilian population |
| Q37740332 | HLA-G and immune evasion in cancer cells |
| Q45261570 | HLA-G polymorphism and breast cancer |
| Q35659589 | HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. |
| Q39698738 | Hepatocyte-targeted psiRNA delivery mediated by galactosylated poly(ethylene glycol)-graft-polyethylenimine in vitro. |
| Q89965508 | High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia |
| Q90573204 | High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma |
| Q36102549 | Human Leukocyte Antigen G Polymorphism and Expression Are Associated with an Increased Risk of Non-Small-Cell Lung Cancer and Advanced Disease Stage |
| Q36051715 | Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer |
| Q79719116 | Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer |
| Q57089345 | Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix |
| Q39725373 | IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer |
| Q33496761 | Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells |
| Q37848665 | Immune parameters affecting the efficacy of chemotherapeutic regimens |
| Q39048293 | Immune selection of tumor cells in TCR β-chain transgenic mice |
| Q33994392 | Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma |
| Q57732968 | Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches |
| Q34491478 | Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association |
| Q37697529 | Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond. |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q38644355 | Intracellular antigens as targets for antibody based immunotherapy of malignant diseases |
| Q46806994 | Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes |
| Q40134652 | Involvement of nonclassical MHC class Ib molecules in heat shock protein-mediated anti-tumor responses |
| Q83821421 | Killer cell immunoglobulin-like receptor genes in patients with breast cancer |
| Q64094854 | Low-Dose Total Body Irradiation Can Enhance Systemic Immune Related Response Induced by Hypo-Fractionated Radiation |
| Q80848518 | Lymph node metastasis density and growth pattern as independent prognostic factors in advanced esophageal squamous cell carcinoma |
| Q92364680 | MHC/HLA Class I Loss in Cancer Cells |
| Q26998490 | MUTYH the base excision repair gene family member associated with colorectal cancer polyposis |
| Q42511974 | Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid. |
| Q27025966 | Monoclonal antibodies for the treatment of cancer |
| Q30990515 | NETWORK-REGULARIZED HIGH-DIMENSIONAL COX REGRESSION FOR ANALYSIS OF GENOMIC DATA. |
| Q35915642 | NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment |
| Q26823400 | NLRC5, at the Heart of Antigen Presentation |
| Q60947027 | Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile |
| Q38522618 | Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? |
| Q37397516 | Natural killer cell tolerance licensing and other mechanisms. |
| Q37616324 | Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy |
| Q37360580 | New diagnostic and molecular characteristics of malignant mesothelioma |
| Q38389316 | New immunotherapeutic strategies for the treatment of neuroblastoma |
| Q28081774 | Overcoming tumor immune evasion with an unique arbovirus |
| Q36675436 | Potential therapeutic role of natural killer cells in cancer |
| Q48353128 | Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. |
| Q38590722 | Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer |
| Q37001690 | Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer |
| Q33801773 | Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells |
| Q36609898 | Review article: immune suppression and colorectal cancer |
| Q26752817 | Sensitivity of Dendritic Cells to Microenvironment Signals |
| Q31021595 | Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer |
| Q37342761 | Surgery as a double-edged sword: a clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses |
| Q47393414 | TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer |
| Q80113417 | TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I |
| Q26797280 | Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity |
| Q48337458 | The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion |
| Q26745580 | The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment |
| Q58566215 | The Interferon-Gamma Paradox in Cancer |
| Q28080338 | The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review |
| Q33767115 | The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. |
| Q35079738 | The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis |
| Q37586041 | The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited |
| Q28296253 | The role of the Major Histocompatibility Complex in the spread of contagious cancers |
| Q37242917 | Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands |
| Q46318048 | Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. |
| Q92524040 | Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function |
| Q34289902 | Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth |
| Q39753147 | Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha |
| Q38076053 | Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. |
| Q28299036 | Vaccines for tumour prevention |
Search more.